Ferri-Dessens RM - Search Results

1

[Multiple pulmonary leiomyomatous nodules: benign metastasing leiomyoma?].

Barlési F, Thomas P, Ferri-Dessens RM, Boniface S, Bonneau V, Kleisbauer JP. Barlési F, et al. Among authors: ferri dessens rm. Rev Mal Respir. 2001 Sep;18(4 Pt 1):440-2. Rev Mal Respir. 2001. PMID: 11547255 French.

2

[Hospital information systems ineffectiveness in costing ambulatory chemotherapy in pulmonary oncology].

Thomas P, Raholimina V, Ferri-Dessens RM, Pibarot M, Penot Ragon C, Gregoire R, Kleisbauer JP. Thomas P, et al. Among authors: ferri dessens rm. Rev Mal Respir. 2000 Jun;17(3):659-63. Rev Mal Respir. 2000. PMID: 10951960 French.

3

[Hospitalization facilities required for quality care of lung cancer patients].

Ferri-Dessens RM, Thomas P, Barlesi F, Raholimina V, Kleisbauer JP. Ferri-Dessens RM, et al. Rev Mal Respir. 2001 Feb;18(1):35-9. Rev Mal Respir. 2001. PMID: 14639175 French.

4

[Management of chronic pain in cancer patients: practical applications].

Ferri-Dessens RM, Thomas P, Barlési F, Kleisbauer JP. Ferri-Dessens RM, et al. Rev Mal Respir. 2001 Feb;18(1):79-85. Rev Mal Respir. 2001. PMID: 14639184 French. No abstract available.

5

Phase I trial of gemcitabine and carboplatin in metastatic non-small-cell lung cancer: a Groupe Français de Pneumo-Cancérologie Study.

Thomas P, Robinet G, Ferri-Dessens RM, Léna H, Gouva S, Vernejoux JM, Kleisbauer JP. Thomas P, et al. Among authors: ferri dessens rm. Lung Cancer. 2002 May;36(2):191-8. doi: 10.1016/s0169-5002(01)00480-9. Lung Cancer. 2002. PMID: 11955654 Clinical Trial.

6

Final results of ERASME-4: a randomized trial of first-line docetaxel plus either capecitabine or epirubicin for metastatic breast cancer.

Bachelot T, Bajard A, Ray-Coquard I, Provencal J, Coeffic D, Agostini C, Boisseau M, Kaphan R, Dramais D, Oprea C, Ferri-Dessens RM, Guastalla JP, Perol D. Bachelot T, et al. Among authors: ferri dessens rm. Oncology. 2011;80(3-4):262-8. doi: 10.1159/000329066. Epub 2011 Jul 6. Oncology. 2011. PMID: 21734418 Clinical Trial.

7

DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity.

Yang CG, Ciccolini J, Blesius A, Dahan L, Bagarry-Liegey D, Brunet C, Varoquaux A, Frances N, Marouani H, Giovanni A, Ferri-Dessens RM, Chefrour M, Favre R, Duffaud F, Seitz JF, Zanaret M, Lacarelle B, Mercier C. Yang CG, et al. Among authors: ferri dessens rm. Cancer Chemother Pharmacol. 2011 Jan;67(1):49-56. doi: 10.1007/s00280-010-1282-4. Epub 2010 Mar 5. Cancer Chemother Pharmacol. 2011. PMID: 20204365 Clinical Trial.

8

Erlotinib in combination with capecitabine (5'dFUR) in resistant pancreatic cancer cell lines.

Chefrour M, Fischel JL, Formento P, Giacometti S, Ferri-Dessens RM, Marouani H, Francoual M, Renée N, Mercier C, Milano G, Ciccolini J. Chefrour M, et al. Among authors: ferri dessens rm. J Chemother. 2010 Apr;22(2):129-33. doi: 10.1179/joc.2010.22.2.129. J Chemother. 2010. PMID: 20435574

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

8 results

Search Page

Filters